TABLE 2.
Baseline characteristics of the NSTEMI patients in different MPO level.
| Characteristics | Overall (N = 271) | Low (N = 129) | Medium (N = 86) | High (N = 56) | p-value |
| Age, years | 65 (57, 73) | 62 (54.75, 71.25) | 65 (59.5, 74) | 67 (62.5, 76.25) | 0.012 |
| Male, n (%) | 188 (69.37) | 99 (76.74) | 61 (70.93) | 28 (50.00) | 0.001 |
| IABP, n (%) | 15 (5.54) | 8 (6.20) | 5 (5.81) | 2 (3.57) | 0.884 |
| Breathing machine, n (%) | 36 (13.3) | 19 (14.7) | 9 (10.50) | 8 (14.3) | 0.671 |
| Heart rate | 74 (63, 84) | 72 (62, 84.25) | 72 (63.5, 83.25) | 78 (65, 84.25) | 0.309 |
| Systolic pressure, mmHg | 133.07 ± 21.55 | 134.56 ± 23.11 | 132.43 ± 20.54 | 130.61 ± 19.31 | 0.493 |
| Diastolic pressure, mmHg | 75 (69, 85) | 75 (67.75, 86.25) | 76 (70, 85) | 75 (67, 82) | 0.597 |
| LVEF, n (%) | 54 (47, 57) | 55 (48.5, 58.75) | 55 (50, 57) | 48 (36, 52.5) | 0.010 |
| Past history | |||||
| Current/former smoking, n (%) | 155 (57.20) | 81 (62.79) | 47 (54.65) | 27 (48.21) | 0.153 |
| Hypertension, n (%) | 176 (64.94) | 78 (60.47) | 58 (67.44) | 40 (71.43) | 0.304 |
| Diabetes, n (%) | 91 (33.58) | 45 (34.88) | 28 (32.56) | 18 (32.14) | 0.902 |
| Previous stroke, n (%) | 55 (20.30) | 21 (16.28) | 20 (23.26) | 14 (25.00) | 0.281 |
| Previous MI, n (%) | 37 (13.65) | 19 (14.73) | 10 (11.63) | 8 (14.29) | 0.825 |
| Hyperlipidemia, n (%) | 208 (77.90) | 103 (80.47) | 67 (79.76) | 38 (69.09) | 0.214 |
| Family history of CAD, n (%) | 28 (10.33) | 16 (12.40) | 8 (9.30) | 4 (7.14) | 0.529 |
| Biochemical characteristics | |||||
| TG, mmol/L | 1.61 (1.2, 2.25) | 1.63 (1.23, 2.32) | 1.59 (1.13, 2.23) | 1.61 (1.23, 2.13) | 0.519 |
| TC, mmol/L | 4.58 (3.76, 5.19) | 4.49 (3.74, 5.12) | 4.61 (3.92, 5.23) | 4.61 (3.56, 5.2) | 0.882 |
| HDL-C, mmol/L | 0.97 (0.85, 1.16) | 0.96 (0.82, 1.14) | 0.98 (0.85, 1.15) | 0.99 (0.85, 1.19) | 0.694 |
| LDL-C, mmol/L | 3.03 (2.3, 3.58) | 3.09 (2.35, 3.68) | 2.88 (2.38, 3.59) | 2.84 (2.17, 3.25) | 0.545 |
| ApoA, g/L | 1.13 (1.03, 1.27) | 1.13 (1.02, 1.29) | 1.12 (1.03, 1.24) | 1.14 (0.98, 1.28) | 0.893 |
| ApoB, g/L | 1.08 (0.87, 1.31) | 1.06 (0.85, 1.31) | 1.11 (0.95, 1.3) | 1.11 (0.87, 1.33) | 0.702 |
| Lp(a), nmol/L | 62.6 (22.18, 129.23) | 67.5 (17.05, 136.2) | 57.4 (26.75, 128.75) | 65.35 (25.78, 113.1) | 0.906 |
| D-Dimer, μg/mL | 0.43 (0.28, 0.72) | 0.42 (0.29, 0.6) | 0.39 (0.27, 1.02) | 0.5 (0.32, 1.03) | 0.15 |
| Cr, μmol/L | 77 (65.75, 95.25) | 77 (65.75, 95.25) | 77 (67.75, 95.25) | 79 (69, 94.75) | 0.621 |
| hsTNT, ng/mL | 0.54 (0.24, 1.39) | 0.49 (0.21, 1.06) | 0.52 (0.23, 1.16) | 0.91 (0.4, 2.1) | 0.013 |
| hs-CRP, mg/L | 5.27 (2.53, 14.74) | 4.29 (1.83, 10.67) | 5.26 (2.76, 19.83) | 10.27 (4.02, 55) | 0.001 |
| leukocyte count,/109 | 8.25 (6.7, 9.91) | 7.71 (6.69, 9.58) | 8.36 (6.51, 9.48) | 9.58 (3.63, 32.99) | <0.001 |
| Neutrophil count,/109 | 5.93 (4.59, 7.65) | 5.55 (4.5, 7.01) | 5.83 (4.5, 7.44) | 7.44 (5.66, 9.36) | <0.001 |
| NT-proBNP, pg/ml | 864.15 (324.13, 2356.75) | 719.85 (219.18, 1688.25) | 821.95 (368.68, 2462.25) | 2116 (575.28, 4537.75) | 0.001 |
| Fibrinogen, g/L | 3.59 (3.02, 4.32) | 3.4 (2.8, 3.93) | 3.62 (3.05, 4.3) | 4.46 (3.56, 5) | <0.001 |
| Killip class | |||||
| Killip I, n (%) | 222 (81.92) | 109 (84.50) | 73 (84.88) | 40 (71.43) | |
| Killip II-IV, n (%) | 49 (18.08) | 20 (15.50) | 13 (15.12) | 16 (28.57) | |
| GRACE score, n (%) | |||||
| <109 | 85 (31.37) | 52 (40.31) | 25 (29.07) | 8 (14.29) | |
| 109–140 | 103 (38.01) | 47 (36.43) | 36 (41.86) | 20 (35.71) | |
| >140 | 83 (30.63) | 30 (23.26) | 25 (29.07) | 28 (50.00) | |
| Revascularization strategy, n (%) | 0.307 | ||||
| MT | 90 (33.21) | 38 (29.46) | 27 (31.40) | 25 (27.78) | |
| PTCA/PCI | 162 (59.78) | 83 (64.34) | 52 (60.47) | 27 (48.21) | |
| CABG | 19 (7.01) | 8 (6.20) | 7 (8.14) | 4 (7.14) | |
| Type of coronary artery disease, n (%) | 0.647 | ||||
| No lesions | 4 (1.83) | 2 (1.82) | 1 (1.43) | 1 (2.63) | |
| Single-vessel lesion | 48 (22.02) | 23 (20.91) | 19 (27.14) | 6 (15.79) | |
| Multi-vessel lesion | 166 (76.15) | 85 (77.27) | 50 (71.43) | 32 (81.58) | |
| Medication during follow-up, n (%) | |||||
| DAPT | 268 (98.89) | 129 (100.00) | 84 (97.67) | 55 (98.21) | 0.203 |
| Beta-blocker | 227 (83.76) | 109 (84.50) | 69 (80.23) | 49 (87.50) | 0.496 |
| ACEI/ARB | 164 (60.52) | 78 (60.47) | 54 (62.79) | 32 (57.14) | 0.802 |
| Anticoagulant | 270 (99.63) | 129 (100.00) | 85 (98.84) | 56 (100.00) | 0.524 |
| Statin | 265 (97.79) | 126 (97.67) | 86 (100.00) | 53 (94.64) | 0.072 |
| Outcome, n (%) | |||||
| Composite MACEs | 36 (13.28) | 9 (6.98) | 12 (13.95) | 15 (26.79) | 0.001 |
| All-cause death | 8 (2.95) | 0 | 3 (3.49) | 5 (8.93) | 0.003 |
| Non-fatal recurrent MI | 8 (2.95) | 3 (2.33) | 4 (4.65) | 1 (1.79) | 0.637 |
| Target lesion revascularization | 14 (5.17) | 4 (3.10) | 3 (3.49) | 7 (12.50) | 0.03 |
| Hospital admission for HF | 11 (4.06) | 2 (1.55) | 5 (5.81) | 4 (7.14) | 0.096 |
IABP, Intra-aortic balloon pump; LVEF, left ventricular ejection fraction; MI, Myocardial infarction; CAD, coronary artery disease; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA, apolipoprotein A; ApoB, apolipoprotein B; Lp-a, Lipoprotein a; Cr, creatinine; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-B type natriuretic peptide; hsTNT, hypersensitive troponin T; GRACE, Global Registry of Acute Coronary Events; MT, medical therapy; PCI, percutaneous coronary Intervention; CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; Composite MACEs, consisted of all-cause death, non-fatal recurrent MI, target lesion revascularization, hospital admission for heart failure.